Constructing an evaluation framework for primary pharmacovigilance systems in developing countries: a case study from China

构建发展中国家一级药物警戒系统评价框架:以中国为例

阅读:2

Abstract

OBJECTIVE: This study aimed to develop an evaluation framework for primary pharmacovigilance systems based on the Chinese context, with potential applicability to regions with similar system maturity. The framework was informed by the WHO manual and tailored to national policies and resource constraints to support consistent pharmacovigilance practices in similar settings and enhance medication safety. METHODS: This study employed semi-structured interviews, literature review, brainstorming, group discussions, and other common methods to establish a preliminary indicator system. The Delphi Method was employed to screen indicators at various levels based on inclusion principles. Subsequently, the Analytic Hierarchy Process (AHP) was applied to determine indicator weights. RESULTS: The effective response rates for both rounds of questionnaires were 100%. Furthermore, the coefficients of reliability were 0.87 and 0.88 for each round, and the Kendall's W for the process and outcome indicators were 0.173 and 0.236. The significance tests for Kendall's W were both P < 0.001. The final evaluation indicator system consisted of 3 first-level indicators, 9 second-level indicators, and 35 third-level indicators. CONCLUSION: This study developed a practical and context-sensitive evaluation framework for primary pharmacovigilance systems in China. The framework offers a feasible assessment tool and may serve as a reference for regions with similar development stages or incomplete pharmacovigilance systems, providing guidance for system improvement and resource allocation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。